New lipid-lowering drugs in hypercholesterolemia

2018-01-11
Ian Graham

Which patients with hypercholesterolemia may be offered new lipid-lowering drugs, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors?

Ian Graham: These would mostly be people at extremely high cardiovascular risk and those with familial hyperlipidemia, particularly familial hyperlipidemia which cannot get the target on statin treatment. Occasionally, high-risk people who cannot take a statin may also be candidates for PCSK9 inhibitors. These are essentially people at the highest risk, particularly those with familial hyperlipidemia in whom you cannot get to the low-density lipoprotein (LDL) target with statins alone or those who are statin intolerant. But there is a problem here, because these are very expensive drugs and will not be available in all cultures.

We would love to hear from you

Comments, mistakes, suggestions?

Partner

Industry Partners

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.